Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2016-04-28 Annual Report
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Rapport financier annuel
Annual Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER 2015' and contains a comprehensive 'Rapport de gestion' (Management Report), detailed financial statements (Bilan, Compte de résultat, Tableau de flux de trésorerie), and notes to the financial statements. It covers the full fiscal year 2015 and is presented to the Annual General Meeting. This structure corresponds to a full Annual Report (10-K equivalent in this context). FY 2015
2016-04-28 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated April 27th, 2016, announcing that an abstract regarding the drug ABX464 has been selected for presentation at the AIDS 2016 Conference. It details clinical trial results (Phase IIa study) and provides updates on future development plans. This content is characteristic of an announcement intended for investors and the public regarding scientific progress and clinical data, which aligns best with an Earnings Release (ER) if it were summarizing period results, or more generally, a news announcement. Since it is not a formal regulatory filing like a 10-K, a comprehensive Interim Report (IR), or a specific management discussion (MDA), and it is announcing scientific/clinical progress rather than just financial results, it functions as a general corporate update. Given the options, this type of announcement, which often accompanies or precedes formal financial reporting periods but focuses on operational/scientific milestones, is frequently categorized under general news releases. However, since it contains detailed clinical data summaries that are often part of an Earnings Release package or a specific Investor Presentation, I must choose the closest fit. It is not a Call Transcript (CT), Investor Presentation (IP), or Management Report (MDA) in the formal sense, but rather a news release detailing progress. In many databases, significant clinical updates released via press release are classified as Earnings Releases (ER) if they are timed around reporting periods, or sometimes as Regulatory Filings (RNS) if no other category fits. Given the focus on clinical data and the announcement format, it is most similar to an Earnings Release (ER) which often includes operational highlights, or RNS as a general announcement. Since it is a press release announcing scientific progress and trial data, and not a formal financial report, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a non-standard announcement, although ER is plausible if this was released concurrently with quarterly results. I will classify it as RNS as it is a general corporate announcement about a scientific milestone, not a formal financial report or presentation.
2016-04-27 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release from ABIVAX dated April 27, 2016, announcing that an abstract concerning their drug candidate ABX464 has been selected for presentation at the 21st International AIDS Conference (AIDS 2016). It details the positive results from a Phase IIa study and mentions future clinical trial plans. This type of announcement, which communicates scientific progress, clinical trial updates, and upcoming conference presentations, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it were summarizing financial results. Since this is a specific announcement about scientific data presentation and clinical development progress, and not a formal regulatory filing (like 10-K or IR) or a general earnings report, it best fits the category for detailed investor-focused information. Given the focus on clinical data and future development strategy, 'Investor Presentation' (IP) is the most appropriate fit, as these press releases often serve as the primary communication vehicle for such updates to investors, even if the actual presentation is later. However, since the document is a press release announcing selection for a conference, and not the presentation itself, and it doesn't fit neatly into ER, AR, or LTR, it could also be considered a general Regulatory Filing (RNS) if the other categories are too specific. Given the high level of detail about clinical trial results and future plans aimed at investors, IP is stronger than RNS. If the document were purely a short notice about the publication of a report, RPA would apply, but this is substantive content about the science.
2016-04-27 French
ABIVAX ABX464-Abstrakt zur Prasentation auf der Welt-AIDS-Konferenz 2016 in Durban, Sudafrika, ausgewahlt
Regulatory Filings Classification · 1% confidence The document is a press release dated April 27, 2016, announcing that an abstract regarding the drug ABX464 has been selected for presentation at the 21st International AIDS Conference (AIDS 2016). It details clinical trial results (Phase IIa), future study plans (Phase IIa/IIb), and provides company background. This type of announcement, focusing on scientific/clinical updates and upcoming conference presentations, is characteristic of an Earnings Release (ER) if it were summarizing period results, or more generally, a news release about corporate activity. Since it is a specific announcement of scientific progress and presentation selection, and not a full financial report (10-K, IR) or a general regulatory filing (RNS), it best fits the 'Earnings Release' category as it communicates key operational/scientific milestones, often released around earnings periods or significant corporate events. However, given the focus is purely on R&D progress and conference acceptance, and not quarterly financial figures, it is a strong candidate for a general news release. Comparing the options, 'ER' (Earnings Release) is often used for major operational updates, but 'RNS' (Regulatory Filings/General Announcement) is the fallback for non-standard news. Since this is a specific, non-financial operational update (scientific presentation acceptance), and it is not a formal report itself, 'RNS' is the most appropriate general classification for a significant, non-mandated news item that doesn't fit the other specific categories like DIV, CAP, or MANG. It is a news announcement, not a full report.
2016-04-27 German
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated April 25th, 2016, announcing that ABIVAX has entered into a manufacturing agreement with PCAS for its drug candidate ABX464. This announcement details a significant business contract related to drug supply for clinical trials and potential future commercial supply. This type of announcement, detailing a strategic business partnership or contract signing that is not a standard financial filing (like 10-K, ER, or IR), best fits the category for Capital/Financing Update (CAP) if it involves securing resources for future operations, or it could be considered a general Regulatory Filing (RNS) if no other category fits well. Since it is a specific agreement securing supply for clinical trials, which is a critical operational and financial step, it is most closely related to securing resources for future operations. However, none of the definitions perfectly capture a 'Manufacturing Agreement Announcement'. It is not an Earnings Release (ER), Interim Report (IR), or a transaction in own shares (POS). Given the options, and recognizing this as a significant corporate event announcement that doesn't fit the specific financial reporting codes, the most appropriate general category for a material, non-standard announcement is Regulatory Filings (RNS), as it is a press release detailing a material corporate development. If 'CAP' were interpreted broadly to include securing operational capacity for future revenue generation, it might fit, but 'RNS' serves as the best catch-all for material press releases not covered elsewhere.
2016-04-25 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release dated April 25, 2016, announcing that ABIVAX has signed a manufacturing contract with PCAS for its drug candidate ABX464. This announcement details a business agreement, supply chain setup, and future clinical trial support. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific announcement regarding a business partnership and supply chain for a drug candidate, which falls under general corporate news. Since there is no specific category for 'Business Partnership Announcement' or 'Supply Agreement,' and it is not a management change (MANG), financing event (CAP), or legal update (LTR), the most appropriate fallback category is 'Regulatory Filings' (RNS) for general regulatory announcements that do not fit elsewhere, although 'LTR' or 'RPA' could be considered if it were announcing the *release* of a more detailed document. Given the content is a direct announcement of a material business event, RNS serves as the best fit among the provided options for non-standard corporate news.
2016-04-25 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.